Ribocure Pharmaceuticals AB, Overseas R&D Center of Ribo Life Science, Completes $33 Million Equity Financing

On July 16, according to official corporate information, Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to as "Ribo Life Science" or "the Company") announced that its overseas R&D center, Ribocure Pharmaceuticals AB ("Ribocure"), had successfully completed a $33 million equity financing.

This round of financing was led by the renowned Swedish investor Mr. Erik Selin, with additional investment from Dr. Jacob Torell, CEO of GoCo Health Innovation City in Gothenburg, Sweden. Following the completion of the financing, Mr. Selin joined the board of directors of Ribocure Pharmaceuticals AB. The successful completion of this financing round marks another significant milestone in the global development of Ribo Life Science.

Ribo Life Science focuses onSmall nucleic acid (siRNA) drugsResearch and development, aligned with the innovative frontier of international small nucleic acid technology, is committed to the iterative R&D of small nucleic acid chemical modification and drug delivery technologies. An independently controlled, fully integrated small nucleic acid drug R&D platform has been established, supporting all stages of small nucleic acid drug research from early development to industrialization. Ribo Life Science has built a rich product pipeline covering cardiovascular, metabolic, liver, kidney, and other therapeutic areas.

Ribocure Pharmaceuticals AB, located in Mölndal, Sweden, serves as the global clinical development and business development base for Ribo Life Science. It boasts a professional team with international vision and global clinical development capabilities, and has established clinical trial sites and laboratories to advance the clinical trials and business development of innovative small nucleic acid drugs worldwide.